|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.348 EUR | +0.15% |
|
+8.36% | -1.61% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Transgene SA reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was EUR 10.34 million compared to EUR 17.41 million a year ago. Net loss was EUR 32.8 million compared to EUR 19.54 million a year ago.
Basic loss per share from continuing operations was EUR 0.33 compared to EUR 0.21 a year ago. Diluted loss per share from continuing operations was EUR 0.33 compared to EUR 0.21 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.61% | 146M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
TRANSGENE 